Prevention strategies of cervical cancer in the HPV vaccine era

This publication has 8 references indexed in Scilit:

• Overview of the European and North American studies on HPV testing in primary cervical cancer screening
  International Journal of Cancer, 2006
• Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
  The Lancet, 2006
• Humoral Immune Response Recognizes a Complex Set of Epitopes on Human Papillomavirus Type 6 L1 Capsomers
  Journal of Virology, 2005
• Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
  The Lancet Oncology, 2005
• Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
  The Lancet, 2004
• A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine
  Vaccine, 2004
• Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women
  Vaccine, 2004
• A Controlled Trial of a Human Papillomavirus Type 16 Vaccine
  New England Journal of Medicine, 2002